College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, China.
Institute of Chinese Veterinary Medicine, Northeast Agricultural University, Harbin 150030, China.
J Agric Food Chem. 2024 Sep 11;72(36):20194-20210. doi: 10.1021/acs.jafc.4c04630. Epub 2024 Aug 28.
Tauroursodeoxycholic acid (TUDCA) is a synthetic bile salt that has demonstrated efficacy in the management of hepatobiliary disorders. However, its specific mechanism of action in preventing and treating nonalcoholic fatty liver disease (NAFLD) remains incompletely understood. This research revealed that TUDCA treatment can reduce obesity and hepatic lipid buildup, enhance intestinal barrier function and microbial balance, and increase the presence of Allobaculum and Bifidobacterium in NAFLD mouse models. TUDCA can influence the activity of farnesoid X receptor (FXR) and cholesterol 7α-hydroxylase (CYP7A1), resulting in higher hepatic bile acid levels and increased expression of sodium taurocholate cotransporting polypeptide (NTCP), leading to elevated concentrations of liver-bound bile acids in mice. Furthermore, TUDCA can inhibit the expression of FXR and fatty acid transport protein 5 (FATP5), thereby reducing fatty acid absorption and hepatic lipid accumulation. This investigation provides new insights into the potential of TUDCA for preventing and treating NAFLD.
牛磺熊脱氧胆酸（TUDCA）是一种合成的胆盐，已被证明在治疗肝胆疾病方面有效。然而，其在预防和治疗非酒精性脂肪性肝病（NAFLD）方面的具体作用机制仍不完全清楚。本研究表明，TUDCA 治疗可减少肥胖和肝脏脂质堆积，增强肠道屏障功能和微生物平衡，并增加 NAFLD 小鼠模型中 Allobaculum 和双歧杆菌的存在。TUDCA 可以影响法尼醇 X 受体（FXR）和胆固醇 7α-羟化酶（CYP7A1）的活性，导致肝脏胆汁酸水平升高，并增加钠离子牛磺胆酸盐共转运蛋白（NTCP）的表达，导致小鼠肝脏结合胆汁酸浓度升高。此外，TUDCA 可以抑制 FXR 和脂肪酸转运蛋白 5（FATP5）的表达，从而减少脂肪酸吸收和肝脏脂质积累。这项研究为 TUDCA 预防和治疗 NAFLD 提供了新的见解。
